April 12, 2005 David Karp Chief Financial Officer Chemokine Therapeutics Corp. Vancouver, BC V6T 1Z3 Canada VIA CAMPUS MAIL Dear Mr. Karp, Re: Amendment to License Agreement between UBC and Chemokine Therapeutics Corporation dated September 22, 1999...License Agreement • April 24th, 2006 • Chemokine Therapeutics Corp • Biological products, (no disgnostic substances)
This letter agreement is to amend the subject of the License. The parties hereby agree to amend the License by making the following changes:
PREFERRED STOCK AND LICENSE RESTRUCTURING AGREEMENTPreferred Stock and License Restructuring Agreement • April 24th, 2006 • Chemokine Therapeutics Corp • Biological products, (no disgnostic substances) • Delaware
THIS PREFERRED STOCK AND LICENSE RESTRUCTURING AGREEMENT (this “Agreement”), is made effective as of the 12th day of April, 2006, by and between Chemokine Therapeutics Corp., a Delaware corporation (“Chemokine”), and Pharmaceutical Product Development, Inc., a North Carolina corporation (“PPD”).
